Whitepaper: USP method modernisation
Posted: 8 December 2021 | Thermo Fisher Scientific | No comments yet
The incorporation of IC to the USP offers a great potential to reduce the number of tests from five to two and significantly simplify any such monograph. Such opportunities not only offer analysts a significant reduction in the number of tests but also introduce the reliability and reproducibility required in a modern GMP laboratory, namely retention time reproducibility, time and cost savings, and overall reduction in user training and system maintenance needs.
Related content from this organisation
- Biopharmaceutical bioseparation systems market to value $20bn
- The importance of sterility testing in biopharmaceutical manufacturing
- HPLC market to grow by $1.26bn in five years
- Coupling large molecules with targeting and delivery mechanisms to augment intracellular delivery
- Radiomolecular precision oncology: a comprehensive treatment approach with high potential
Related topics
Analytical techniques, Biologics, Biopharmaceuticals, Chromatography, Data integrity, Drug Delivery Systems, Excipients, Formulation, Good Manufacturing Practice (GMP), Ingredients, Lab Automation, Manufacturing, Outsourcing, QA/QC, Regulation & Legislation, Research & Development (R&D)